FDA schedules panel for Novo's insulin products

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said FDA tentatively scheduled a Nov. 8 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs for insulin Degludec and insulin Deglu...